Bioventus (BVS) Scheduled to Post Quarterly Earnings on Tuesday

Bioventus (NYSE:BVS) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Bioventus has set its FY 2024 guidance at 0.120-0.200 EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, March 12th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $135.42 million for the quarter, compared to analyst estimates of $124.84 million. Bioventus had a negative net margin of 30.49% and a positive return on equity of 2.25%. On average, analysts expect Bioventus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Bioventus Trading Up 0.3 %

Shares of NYSE:BVS opened at $3.97 on Friday. The firm has a fifty day moving average of $4.88 and a two-hundred day moving average of $4.55. The company has a quick ratio of 1.01, a current ratio of 1.53 and a debt-to-equity ratio of 1.66. Bioventus has a 12-month low of $0.86 and a 12-month high of $6.08. The firm has a market capitalization of $314.30 million, a P/E ratio of -1.58 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum boosted their target price on Bioventus from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 13th.

Insider Transactions at Bioventus

In related news, CFO Mark Leonard Singleton sold 5,541 shares of the firm’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $5.39, for a total value of $29,865.99. Following the transaction, the chief financial officer now directly owns 25,665 shares of the company’s stock, valued at approximately $138,334.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 15,720 shares of company stock worth $80,435. 29.10% of the stock is owned by corporate insiders.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.